demonstratedthathigh-dosestatintreatment,reducingLDLsurrogateendpointtrials,and3wereclinicalendpointtrials. cholesteroltosubstantially100mg/dl(2.6mmol/L),pro-In21trials,patientswereenrolledinaninitial2-to8-week videdadditionalclinicalbenefittomoderatetherapy.2Al-placeborun-inperiodthatallowedlipidlevelstostabilize...